Study to Evaluate the Efficacy, Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Sapablursen (Formerly ISIS 702843, IONIS-TMPRSS6-LRx)

PHASE2TerminatedINTERVENTIONAL
Enrollment

29

Participants

Timeline

Start Date

September 24, 2020

Primary Completion Date

March 28, 2023

Study Completion Date

March 28, 2023

Conditions
Beta Thalassemia Intermedia
Interventions
DRUG

sapablursen

sapablursen administered subcutaneously

Trial Locations (19)

1330

Cukurova Üniversitesi Tıp Fakültesi, Adana

2050

Royal Prince Alfred Hospital, Camperdown

3168

Monash Medical Centre, Clayton

6000

Royal Perth Hospital, Perth

6100

Hacettepe Üniversitesi Tıp Fakültesi, Ankara

10330

King Chulalongkorn Memorial Hospital, Pathum Wan

10700

Siriraj Hospital, Bangkok

12120

Thammasat University Hospital, Pathum Thani

34093

İstanbul Üniversitesi - Istanbul Tıp Fakültesi, Topkapı

35100

Ege Universitesi Tip Fakultesi, Izmir

40002

Srinagarind Hospital, Khon Kaen

50200

Maharaj Nakorn Chiang Mai Hospital, Chiang Mai

65000

Naresuan University Hospital, Phitsanulok

90110

Songklanagarind Hospital, Songkhla

115 27

Aghia Sophia General Children's Hospital, Athens

26 504

University General Hospital of Patras, Patra

412 21

Koutlimbaneio & Triantafylleio General Hospital of Larissa, Larissa

Unknown

Chronic Care Center, Hazmiyeh

07070

Akdeniz University Faculty of Medicine, Antalya

Sponsors
All Listed Sponsors
lead

Ionis Pharmaceuticals, Inc.

INDUSTRY